The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Cuffless Non-invasive Blood Pressure Measuring Devices--Clinical Performance Testing and Evaluation." This draft guidance provides recommendations for clinical performance testing and evaluation to support premarket submissions for cuffless non-invasive blood pressure measuring devices. This draft guidance is not final nor is it for implementation at this time.

Original title: “Cuffless Non-Invasive Blood Pressure Measuring Devices-Clinical Performance Testing and Evaluation; Draft Guidance for Industry and Food and Drug Administration Staff; Availability”

Original title: “Charter Amendments, Establishments, Reestablishments, Renewals, and Terminations; Sickle Cell Advisory Committee”

The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Tyler Jordan Hall for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Hall was convicted of a felony under Federal law for introduction of unapproved drugs into interstate commerce. The factual basis supporting Mr. Hall's conviction, as described below, is conduct relating

Original title: “Tyler Jordan Hall: Final Debarment Order”

The Administration for Children and Families (ACF) is proposing to resume collecting data for the Procedures for Requests from Tribal Lead Agencies to use Child Care and Development Fund (CCDF) Funds for Construction or Major Renovation of Child Care Facilities. This information collection was previously approved by the Office of Management and Budget. The Office of Child Care (OCC) is proposing to extend approval of the information collection with changes, significantly reducing the burden for

Original title: “Proposed Information Collection Activity; Procedures for Requests From Tribal Lead Agencies To Use Child Care and Development Funds for Construction or Major Renovation of Child Care Facilities”

The Administration for Children and Families (ACF) Office of Planning, Research, and Evaluation (OPRE) is requesting a 3-year extension with revisions to the information collection activities approved by the Office of Management and Budget (OMB): ACF Congressionally Directed Community Projects--Universal Project Description (CDCP-UPD)(OMB#: 0970-0604, expiration March 31, 2026). Revisions are based on lessons learned from previous years. Language is simplified for application requirements. This

Original title: “Proposed Information Collection Activity; Administration for Children and Families Congressionally Directed Community Projects-Uniform Project Description”

This report evaluates CureTB program performance during 2016-2023.

Original title: “Continuity of Care for Patients with Tuberculosis Relocating to Other Countries — CureTB Program, 2016–2023”

This report describes the prevalence of physical and sexual violence perpetration by young men and associations of these events with their exposure to violence during childhood.

Original title: “Prevalence of Violence Perpetration by Men Aged 18–24 Years in Low- and Middle-Income Countries Who Were Exposed to Violence During Childhood — Eight Countries, 2018–2023”

Agency to focus on next-generation, validated research models.

Original title: “NIH Announces Major Policy Shift to End Use of Human Fetal Tissue in NIH-Supported Research”

U.S. exits WHO, citing COVID-19 failures, politicization, and shift to bilateral health efforts.

Original title: “United States Completes WHO Withdrawal”

Risk factors for congenital cerebral palsy, and how to prevent it before, during, and after birth.

Original title: “Risk Factors for Cerebral Palsy”

Learn how CDC fulfills its public health mission while being a responsible steward to taxpayers.

Original title: “Finance”

Original title: “Older Adult Health”

Notice is provided that the Chief of Staff, who has the Delegated Authority of the Indian Health Service (IHS) Director has approved the rates for inpatient and outpatient medical care provided by the IHS facilities for Calendar Year 2026.

Original title: “Reimbursement Rates for Calendar Year 2026”

The Food and Drug Administration (FDA or we) received a citizen petition from Celiac Journey requesting that we act to protect consumers with celiac disease by requiring that all ingredients with gluten be listed by name in the ingredient list and by requiring cross- contact controls with gluten-containing grains. We are issuing this document to request comment on the issues raised in the petition and on specific questions related to these issues.

Original title: “Labeling and Preventing Cross-Contact of Gluten for Packaged Foods; Request for Information”

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled "FDA Records Access Authority for Cosmetics: Guidance for Industry." The draft guidance document provides answers to frequently asked questions about certain authorities for FDA to access records related to cosmetic products. It is intended to inform regulated industry about the Agency's current thinking regarding the criteria, process, and expectations for FDA's access to these reco

Original title: “FDA Records Access Authority for Cosmetics; Draft Guidance for Industry; Availability”

In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institutes of Health Office of the Director (OD) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Original title: “Proposed Collection; 60-Day Comment Request; The Genetic Testing Registry (Office of the Director)”

The U.S. Food and Drug Administration today announced its initial review of the effectiveness of the FDA ImportShield Program (FISP), which launched in August 2025 to modernize how the FDA reviews imported products.

Original title: “FDA ImportShield Program Delivers Impressive Results in Strengthening FDA Oversight at U.S. Ports of Entry”

Today, the U.S. Food and Drug Administration issued a Request for Information (RFI) regarding labeling and preventing cross-contact of gluten in packaged food.

Original title: “FDA Takes Steps to Improve Gluten Ingredient Disclosure in Foods”

Our community’s advocacy is working! Congress is listening to the powerful outreach from our rare disease community.   Lawmakers have released a draft legislative package that includes a five-year reauthorization of the Rare Pediatric Disease […] The post PRV Reauthorization Included in Draft Congressional Appropriations Package appeared first on EveryLife Foundation for Rare Diseases.

Original title: “PRV Reauthorization Included in Draft Congressional Appropriations Package”

At its January meeting, EMA’s Committee for Herbal Medicinal Products…, “The HMPC, through its high-quality scientific recommendations, plays a vital role in harmonising the regulation of herbal medicinal products and substance in the EU. A…, The HMPC is the committee responsible for compiling and assessing scientific data on herbal substances, preparations and combinations, to support the harmonisation of…

Original title: “Carmen Purdel elected as new chair of the Committee for Herbal Medicinal Products”